J Korean Med Sci.  2024 Apr;39(14):e128. 10.3346/jkms.2024.39.e128.

Comparative Analysis of Clinical Outcomes Using Propensity Score Matching: Coronavirus Disease 2019 vs. Seasonal Influenza in Korea

• Sim JK
• Lee HS
• Yang J
• Gwack J
• Kim BI
• Cha Jo
• Min KH
• Lee YS
• obotSARI(I

• KMID: 2554584
• DOI: http://doi.org/10.3346/jkms.2024.39.e128

Abstract

Background
The advent of the omicron variant and the formulation of diverse therapeutic strategies marked a new epoch in the realm of coronavirus disease 2019 (COVID-19). Studies have compared the clinical outcomes between COVID-19 and seasonal influenza, but such studies were conducted during the early stages of the pandemic when effective treatment strategies had not yet been developed, which limits the generalizability of the findings. Therefore, an updated evaluation of the comparative analysis of clinical outcomes between COVID-19 and seasonal influenza is requisite.
Methods
This study used data from the severe acute respiratory infection surveillance system of South Korea. We extracted data for influenza patients who were infected between 2018 and 2019 and COVID-19 patients who were infected in 2021 (pre-omicron period) and 2022 (omicron period). Comparisons of outcomes were conducted among the pre-omicron, omicron, and influenza cohorts utilizing propensity score matching. The adjusted covariates in the propensity score matching included age, sex, smoking, and comorbidities.
Results
The study incorporated 1,227 patients in the pre-omicron cohort, 1,948 patients in the omicron cohort, and 920 patients in the influenza cohort. Following propensity score matching, 491 patients were included in each respective group. Clinical presentations exhibited similarities between the pre-omicron and omicron cohorts; however, COVID-19 patients demonstrated a higher prevalence of dyspnea and pulmonary infiltrates compared to their influenza counterparts. Both COVID-19 groups exhibited higher in-hospital mortality and longer hospital length of stay than the influenza group. The omicron group showed no significant improvement in clinical outcomes compared to the pre-omicron group.
Conclusion
The omicron group did not demonstrate better clinical outcomes than the pre-omicron group, and exhibited significant disease severity compared to the influenza group. Considering the likely persistence of COVID-19 infections, it is imperative to sustain comprehensive studies and ongoing policy support for the virus to enhance the prognosis for individuals affected by COVID-19.

Keyword

COVID-19; Influenza; Omicron Variant; Clinical Outcomes

Figure

• 

  Fig. 1 Flowchart of patient selection.COVID-19 = coronavirus disease 2019.

Reference

1. Onyeaka H, Anumudu CK, Al-Sharify ZT, Egele-Godswill E, Mbaegbu P. COVID-19 pandemic: a review of the global lockdown and its far-reaching effects. Sci Prog. 2021; 104(2):368504211019854. PMID: 34061685.

2. Rennert-May E, Leal J, Thanh NX, Lang E, Dowling S, Manns B, et al. The impact of COVID-19 on hospital admissions and emergency department visits: a population-based study. PLoS One. 2021; 16(6):e0252441. PMID: 34061888.

3. Horita N, Fukumoto T. Global case fatality rate from COVID-19 has decreased by 96.8% during 2.5 years of the pandemic. J Med Virol. 2023; 95(1):e28231. PMID: 36253938.

4. Bhimraj A, Morgan RL, Shumaker AH, Baden L, Cheng VC, Edwards KM, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2022; ciac724. PMID: 36063397.

5. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020; 383(27):2603–2615. PMID: 33301246.

6. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384(5):403–416. PMID: 33378609.

7. Ferreyro BL, Angriman F, Munshi L, Del Sorbo L, Ferguson ND, Rochwerg B, et al. Association of noninvasive oxygenation strategies with all-cause mortality in adults with acute hypoxemic respiratory failure: a systematic review and meta-analysis. JAMA. 2020; 324(1):57–67. PMID: 32496521.

8. Ehrmann S, Li J, Ibarra-Estrada M, Perez Y, Pavlov I, McNicholas B, et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med. 2021; 9(12):1387–1395. PMID: 34425070.

9. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022; 399(10332):1303–1312. PMID: 35305296.

10. Perez-Guzman PN, Knock E, Imai N, Rawson T, Elmaci Y, Alcada J, et al. Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England. Nat Commun. 2023; 14(1):4279. PMID: 37460537.

11. Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021; 9(3):251–259. PMID: 33341155.

12. Brehm TT, van der Meirschen M, Hennigs A, Roedl K, Jarczak D, Wichmann D, et al. Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza. Sci Rep. 2021; 11(1):5803. PMID: 33707550.

13. Ludwig M, Jacob J, Basedow F, Andersohn F, Walker J. Clinical outcomes and characteristics of patients hospitalized for influenza or COVID-19 in Germany. Int J Infect Dis. 2021; 103:316–322. PMID: 33279652.

14. de Marignan D, Vacheron CH, Ader F, Lecocq M, Richard JC, Frobert E, et al. A retrospective comparison of COVID-19 and seasonal influenza mortality and outcomes in the ICUs of a French university hospital. Eur J Anaesthesiol. 2022; 39(5):427–435. PMID: 35200203.

15. López Montesinos I, Arrieta-Aldea I, Dicastillo A, Zuccarino F, Sorli L, Guerri-Fernández R, et al. Comparison of hospitalized coronavirus disease 2019 and influenza patients requiring supplemental oxygen in a cohort study: clinical impact and resource consumption. Clin Infect Dis. 2022; 75(12):2225–2238. PMID: 35442442.

16. Fröhlich GM, De Kraker ME, Abbas M, Keiser O, Thiabaud A, Roelens M, et al. Hospital outcomes of community-acquired COVID-19 versus influenza: insights from the Swiss hospital-based surveillance of influenza and COVID-19. Euro Surveill. 2022; 27(1):2001848. PMID: 34991775.

17. Lee YS, Kang M, Cho J, Kang D, Min KH, Suh GY, et al. Nationwide social distancing and the epidemiology of severe acute respiratory infections. Yonsei Med J. 2021; 62(10):954–957. PMID: 34558876.

18. Fitzner J, Qasmieh S, Mounts AW, Alexander B, Besselaar T, Briand S, et al. Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection. Bull World Health Organ. 2018; 96(2):122–128. PMID: 29403115.

19. Lee JJ, Choe YJ, Jeong H, Kim M, Kim S, Yoo H, et al. Importation and transmission of SARS-CoV-2 B.1.1.529 (Omicron) variant of concern in Korea, November 2021. J Korean Med Sci. 2021; 36(50):e346. PMID: 34962117.

20. Ryu B, Shin E, Kim NY, Kim DH, Lee H, Kim A, et al. Severity of COVID-19 associated with SARS-CoV-2 variants circulating in the Republic of Korea. Public Health Wkly Rep. 2022; 15(47):2873–2895.

21. Heydarifard Z, Shafiei-Jandaghi NZ, Safaei M, Tavakoli F, Shatizadeh Malekshahi S. Comparison of clinical outcomes, demographic, and laboratory characteristics of hospitalized COVID-19 patients during major three waves driven by alpha, delta, and omicron variants in Tehran, Iran. Influenza Other Respi Viruses. 2023; 17(8):e13184.

22. Mondi A, Mastrorosa I, Piselli P, Cimaglia C, Matusali G, Carletti F, et al. Evolution of SARS-CoV-2 variants of concern over a period of delta and omicron cocirculation, among patients hospitalized for COVID-19 in an Italian reference hospital: impact on clinical outcomes. J Med Virol. 2023; 95(6):e28831. PMID: 37246793.

23. Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022; 22(7):1002–1010. PMID: 35405090.

24. Choi Y, Kang M, Shin DH, Jung J, Choi SJ, Kim NH, et al. Antibiotic prescription in patients with coronavirus disease 2019: analysis of national health insurance system data in the Republic of Korea. J Korean Med Sci. 2023; 38(25):e189. PMID: 37365725.

25. Cobb NL, Sathe NA, Duan KI, Seitz KP, Thau MR, Sung CC, et al. Comparison of clinical features and outcomes in critically ill patients hospitalized with COVID-19 versus influenza. Ann Am Thorac Soc. 2021; 18(4):632–640. PMID: 33183067.

26. Auvinen R, Nohynek H, Syrjänen R, Ollgren J, Kerttula T, Mäntylä J, et al. Comparison of the clinical characteristics and outcomes of hospitalized adult COVID-19 and influenza patients - a prospective observational study. Infect Dis (Lond). 2021; 53(2):111–121. PMID: 33170050.

27. Kim SH, Wi YM, Lim S, Han KT, Bae IG. Differences in clinical characteristics and chest images between coronavirus disease 2019 and influenza-associated pneumonia. Diagnostics (Basel). 2021; 11(2):261. PMID: 33567507.

28. Mella-Torres A, Escobar A, Barrera-Avalos C, Vargas-Salas S, Pirazzoli M, Gonzalez U, et al. Epidemiological characteristics of omicron and delta SARS-CoV-2 variant infection in Santiago, Chile. Front Public Health. 2022; 10:984433. PMID: 36339233.

29. Lyons PG, Bhavani SV, Mody A, Bewley A, Dittman K, Doyle A, et al. Hospital trajectories and early predictors of clinical outcomes differ between SARS-CoV-2 and influenza pneumonia. EBioMedicine. 2022; 85:104295. PMID: 36202054.

30. Flerlage T, Boyd DF, Meliopoulos V, Thomas PG, Schultz-Cherry S. Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. Nat Rev Microbiol. 2021; 19(7):425–441. PMID: 33824495.

31. Hui KP, Ng KC, Ho JC, Yeung HW, Ching RH, Gu H, et al. Replication of SARS-CoV-2 omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract. EBioMedicine. 2022; 83:104232. PMID: 35988466.

32. Hui KP, Ho JC, Cheung MC, Ng KC, Ching RH, Lai KL, et al. SARS-CoV-2 omicron variant replication in human bronchus and lung ex vivo. Nature. 2022; 603(7902):715–720. PMID: 35104836.

33. Bhattacharyya RP, Hanage WP. Challenges in inferring intrinsic severity of the SARS-CoV-2 omicron variant. N Engl J Med. 2022; 386(7):e14. PMID: 35108465.

34. Meurisse M, Van Oyen H, Blot K, Catteau L, Serrien B, Klamer S, et al. Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data. BMC Infect Dis. 2022; 22(1):839. PMID: 36368977.

35. Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, Peacock SJ, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023; 21(3):162–177. PMID: 36653446.

36. Hong J, Park AK, Radnaabaatar M, Kim EJ, Kim DW, Jung J. The impact of entry restrictions on the spread of severe acute respiratory syndrome coronavirus variants between 2021 and 2022. J Korean Med Sci. 2023; 38(28):e223. PMID: 37463690.

37. Kim S, Park JO, Lee HA, Park HA, Lee CA, Wang SJ, et al. Unintended beneficial effects of COVID-19 on influenza-associated emergency department use in Korea. Am J Emerg Med. 2022; 59:1–8. PMID: 35772222.

38. Noh JY, Seong H, Yoon JG, Song JY, Cheong HJ, Kim WJ. Social distancing against COVID-19: implication for the control of influenza. J Korean Med Sci. 2020; 35(19):e182. PMID: 32419400.

39. Park AK, Kim IH, Lee CY, Kim JA, Lee H, Kim HM, et al. Rapid emergence of the omicron variant of severe acute respiratory syndrome coronavirus 2 in Korea. Ann Lab Med. 2023; 43(2):211–213. PMID: 36281518.

40. Su S, Chaves SS, Perez A, D’Mello T, Kirley PD, Yousey-Hindes K, et al. Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection. Clin Infect Dis. 2014; 59(2):252–255. PMID: 24748521.

41. Yoon JG, Noh JY, Choi WS, Lee J, Lee JS, Wie SH, et al. A comparison of epidemiology and clinical outcomes between influenza A H1N1pdm09 and H3N2 based on multicenter surveillance from 2014 to 2018 in South Korea. Influenza Other Respi Viruses. 2021; 15(1):99–109.

42. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of, and effectiveness of mRNA vaccines against, COVID-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376:e069761. PMID: 35264324.